IOVS AJP: Gastrointestinal and Liver Physiology
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

(Investigative Ophthalmology and Visual Science. 2003;44:2390-2398.)
© 2003 by The Association for Research in Vision and Ophthalmology, Inc.
DOI:  10.1167/iovs.02-1052
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Klisovic, D. D.
Right arrow Articles by Marcucci, G.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Klisovic, D. D.
Right arrow Articles by Marcucci, G.

Depsipeptide (FR901228) Inhibits Proliferation and Induces Apoptosis in Primary and Metastatic Human Uveal Melanoma Cell Lines

Dino D. Klisovic,1 Steven E. Katz,1 David Effron,2 Marko I. Klisovic,3 Joseph Wickham,4 Mark R. Parthun,4 Martin Guimond,3 and Guido Marcucci3

1From the William H. Havener Eye Center and the 3Department of Internal Medicine, Division of Hematology and Oncology, and the 4Department of Molecular and Cellular Biochemistry, The Ohio State University, Columbus, Ohio; and the 2Wexner Institute for Pediatric Research, Children’s Hospital, Columbus, Ohio.

PURPOSE. Uveal melanoma (UM) is the most common primary malignant ocular tumor in adults. No effective chemotherapy regimens are available for either intraocular or metastatic uveal melanoma. Therefore, the ability of the histone deacetylase inhibitors (HDACIs), depsipeptide, sodium butyrate (NaB) and trichostatin A (TSA), to induce apoptosis and inhibit cell growth of UM cell lines in vitro was examined.

METHODS. Three primary and two metastatic UM cell lines were treated in vitro with different concentrations of histone deacetylase inhibitors (HDACIs). Cell proliferation was studied in 24-well plates. Induction of apoptosis was studied by flow cytometry. Changes in gene expression of Fas/FasL, p21Waf/Cip1, and p27Kip1 were studied by RT-PCR. Western blot analysis was used to study histone acetylation, Fas/FasL, p21Waf/Cip1, p27Kip1 and caspase-3 protein levels. Real-time PCR was used to study changes in bcl-2/bax gene expression.

RESULTS. A dose-dependent increase in histone acetylation was observed in all cell lines. This corresponded to significant inhibition of cell growth and induction of apoptosis in all melanoma cell lines in a concentration-dependent manner. Western blot analysis revealed dose-dependent increases in the amount of caspase-3, Fas/FasL, p21Waf/Cip1, and p27Kip1 proteins. However, no changes in bcl-2/bax gene expression were detected by real-time PCR.

CONCLUSIONS. HDACIs are potent inhibitors of primary and metastatic UM cell growth in vitro. The apoptosis is probably mediated through the Fas/FasL signaling pathway, whereas bcl-2 appears not to be involved. These data support further clinical evaluation of depsipeptide and other HDACIs in patients with primary and metastatic UM.




This article has been cited by other articles:


Home page
 Arch OphthalmolHome page
T. S. Cunneen, R. M. Conway, and M. C. Madigan
In Vitro Effects of Histone Deacetylase Inhibitors and Mitomycin C on Tenon Capsule Fibroblasts and Conjunctival Melanoma Cells
Arch Ophthalmol, April 1, 2009; 127(4): 414 - 420.
[Abstract] [Full Text] [PDF]

Home page
 J. Pharmacol. Exp. Ther.Home page
S. Liu, R. B. Klisovic, T. Vukosavljevic, J. Yu, P. Paschka, L. Huynh, J. Pang, P. Neviani, Z. Liu, W. Blum, et al.
Targeting AML1/ETO-Histone Deacetylase Repressor Complex: A Novel Mechanism for Valproic Acid-Mediated Gene Expression and Cellular Differentiation in AML1/ETO-Positive Acute Myeloid Leukemia Cells
J. Pharmacol. Exp. Ther., June 1, 2007; 321(3): 953 - 960.
[Abstract] [Full Text] [PDF]

Home page
 Molecular Cancer TherapeuticsHome page
M. Entin-Meer, A. Rephaeli, X. Yang, A. Nudelman, S. R. VandenBerg, and D. A. Haas-Kogan
Butyric acid prodrugs are histone deacetylase inhibitors that show antineoplastic activity and radiosensitizing capacity in the treatment of malignant gliomas
Mol. Cancer Ther., December 1, 2005; 4(12): 1952 - 1961.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
J. C. Byrd, G. Marcucci, M. R. Parthun, J. J. Xiao, R. B. Klisovic, M. Moran, T. S. Lin, S. Liu, A. R. Sklenar, M. E. Davis, et al.
A phase 1 and pharmacodynamic study of depsipeptide (FK228) in chronic lymphocytic leukemia and acute myeloid leukemia
Blood, February 1, 2005; 105(3): 959 - 967.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
D. Bandyopadhyay, A. Mishra, and E. E. Medrano
Overexpression of Histone Deacetylase 1 Confers Resistance to Sodium Butyrate-Mediated Apoptosis in Melanoma Cells through a p53-Mediated Pathway
Cancer Res., November 1, 2004; 64(21): 7706 - 7710.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
R. L. Piekarz, R. W. Robey, Z. Zhan, G. Kayastha, A. Sayah, A. H. Abdeldaim, S. Torrico, and S. E. Bates
T-cell lymphoma as a model for the use of histone deacetylase inhibitors in cancer therapy: impact of depsipeptide on molecular markers, therapeutic targets, and mechanisms of resistance
Blood, June 15, 2004; 103(12): 4636 - 4643.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2003 by the Association for Research in Vision and Ophthalmology